Latest News
-
Monday - October 1, 2012
Not intended for U.S. and UK Media
Bayer HealthCare enters into multi-target alliance to fight endometriosis » more
-
Monday - October 1, 2012
Not intended for US or UK use! - Bayer Launches New Mobil Application (APP)
App ‘SKIN PEACE’ advises How to Use Topical Corticosteroid for Eczema Correctly » more
-
Friday - September 28, 2012
Not intended for US or UK use! - Atopic Dermatitis: CALM-IT Task Force at EADV 2012
Pruritus Relief within the First Hours after Application of Methyl-prednisolone Aceponate 0.1% to Treat Nickel Sulfate-Induced Eczema » more
-
Friday - September 28, 2012
Not intended for U.S. and UK Media
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan » more
-
Thursday - September 27, 2012
Not Intended for U.S. and U.K. Media
Bayer’s Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Stivarga shown in a pivotal Phase III trial to extend overall survival in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after previous treatments » more
-
Thursday - September 27, 2012
Not intended for US or UK use! - EADV Congress 2012
International consensus group introduces recommendations and treatment algorithms for hemorrhoidal disease » more
-
Thursday - September 27, 2012
Not intended for US or UK use! - EADV Congress 2012
New data suggest an increase in reactive oxygen species in the antibacterial action of isoconazole nitrate » more
-
Wednesday - September 26, 2012
Support of Family Planning Programs:
Bayer Joins Global Initiative for Better Access to Safe and Effective Contraception
Initiative includes the Government of Norway and other partners as well as Bayer HealthCare as the manufacturer of the contraceptive implant Jadelle / Bayer HealthCare prepared to halve the price of its WHO prequalified contraceptive implants Jadelle subject to certain volume guarantees / Initiative complements Bayer HealthCare's overall commitment to “Access to Medicine” focusing on Neglected Tropical Diseases like Chagas disease in Latin America and the African sleeping sickness (in cooperation with WHO), as well as tuberculosis (together with the TB Alliance) » more
-
Wednesday - September 26, 2012
Exemplary rehabilitation of a commercial building in Bottrop:
Bayer’s network of experts supporting future building in Germany
Comprehensive modernization through EcoCommercial Building Program / Combination of measures expected to produce energy surplus » more
-
Saturday - September 22, 2012
International award from Bayer Science & Education Foundation:
Climate researcher Markku Kulmala honored with Bayer Climate Award 2012
Honored for pioneering work on aerosols as a climate factor / Bayer Board of Management member Wolfgang Plischke: “To solve global challenges, we need innovative research contributions” / Prize awarded at Annual Assembly of Leopoldina in Berlin » more
-
Friday - September 21, 2012
Not intended for U.S. and UK media
U.S. FDA Approves EYLEA® (aflibercept) Injection for the Treatment of Central Retinal Vein Occlusion
Bayer plans to submit for marketing authorization in CRVO end of 2012 in Europe » more
-
Friday - September 21, 2012
Not intended for U.S. and UK Media
VEGF Trap-Eye (aflibercept ophthalmic injection) Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
Decision of European Commission on approval expected in fourth quarter 2012 » more
-
Thursday - September 20, 2012
For use outside the US and UK only
Bayer submits marketing application for new transparent low dose contraceptive patch in the EU » more
-
Thursday - September 20, 2012
Bayer CropScience: Geared for Sustainable Growth
EUR 7 billion investment program to fuel further growth
EUR 5 billion earmarked for Research and Development between 2011 and 2016 / Investments of EUR 2 billion in production capacities and seed processing facilities / Strong integrated pipeline with at least EUR 4 billion peak sales potential / Share of Seeds business to double to 20 percent by 2016 » more
-
Tuesday - September 18, 2012
Bayer Science & Education Foundation:
New scholarships worth EUR 200,000 awarded by Bayer’s foundation to promote international talent
Funding for ambitious study projects and international work / Focus on the fields of science, technology and medicine / Hermann Strenger scholarships for international vocational projects / Scholarships worth over EUR 1 million awarded to 199 young people since 2007 » more
-
Monday - September 17, 2012
Not intended for U.S. and UK media - 37th European Society for Medical Oncology (ESMO) Congress:
Bayer to Present Data on Several Oncology Compounds at ESMO 2012 Congress
Updated overall survival results for CORRECT study of regorafenib in the treatment of metastatic colorectal cancer presented as a late-breaking abstract and data of regorafenib in gastrointestinal stromal tumor (GIST) presented in oral presentation session / Updated survival, quality of life (QOL), and safety data from Phase III trial ALSYMPCA of radium-223 dichloride in castration-resistant prostate cancer presented in poster session / Data from Phase III trials with Nexavar® combined with Tarceva® in liver cancer and Nexavar in non-small cell lung cancer (NSCLC) presented as late-breaking abstracts in oral sessions » more
-
Friday - September 14, 2012
Not intended for U.S. and UK media - Highly effective technology for the treatment of peripheral artery disease
Bayer HealthCare introduces Jetstream™ Atherectomy System to European markets » more
-
Friday - September 14, 2012
Change of chairmanship effective October 1, 2012
Werner Wenning elected Chairman of the Supervisory Board of Bayer AG
Dr. Manfred Schneider to step down after more than ten years » more
-
Friday - September 14, 2012
Not intended for U.S. Media
Bayer HealthCare to acquire US-animal health business from Teva Pharmaceutical Industries
Acquisition enables Bayer HealthCare to expand companion animal and food animal product lines » more
-
Thursday - September 13, 2012
Renewed inclusion in Dow Jones Sustainability Indices:
Bayer remains “best in class” in sustainability
Indices offer institutional investors a guide for making sustainable investments » more
Copyright @ Bayer AG
Search
Publications
research – The Bayer Scientific Magazine
Stockholders' Newsletter
Annual Report
Sustainable Development Report
Publications Overview
Newsletter
Events
Download Center - Selection
Bayer TV
